160 related articles for article (PubMed ID: 19276301)
21. Increased soluble vascular cell adhesion molecule 1 concentrations in patients with primary or systemic lupus erythematosus-related antiphospholipid syndrome: correlations with the severity of thrombosis.
Kaplanski G; Cacoub P; Farnarier C; Marin V; Grégoire R; Gatel A; Durand JM; Harlé JR; Bongrand P; Piette JC
Arthritis Rheum; 2000 Jan; 43(1):55-64. PubMed ID: 10643700
[TBL] [Abstract][Full Text] [Related]
22. Assessment of serum vascular endothelial growth factor and nail fold capillaroscopy changes in systemic lupus erythematosus with and without cutaneous manifestations.
Moneib HA; Salem SA; Aly DG; Khedr HT; Wafaey HA; Hassan HE
J Dermatol; 2012 Jan; 39(1):52-7. PubMed ID: 21950586
[TBL] [Abstract][Full Text] [Related]
23. Serum levels of three angiogenic factors in systemic lupus erythematosus and their clinical significance.
Zhou L; Lu G; Shen L; Wang L; Wang M
Biomed Res Int; 2014; 2014():627126. PubMed ID: 24511540
[TBL] [Abstract][Full Text] [Related]
24. Real-time PCR of CD146 mRNA in peripheral blood enables the relative quantification of circulating endothelial cells and is an indicator of angiogenesis.
Fürstenberger G; von Moos R; Senn HJ; Boneberg EM
Br J Cancer; 2005 Oct; 93(7):793-8. PubMed ID: 16160694
[TBL] [Abstract][Full Text] [Related]
25. Effect of disease activity and corticosteroids on serum levels of soluble endothelial cell protein C receptor in patients with systemic lupus erythematosus.
Koarada S; Tsuneyoshi N; Haruta Y; Tada Y; Mitamura M; Inoue H; Ohta A; Fukudome K; Nagasawa K
Mod Rheumatol; 2009; 19(2):173-9. PubMed ID: 19067109
[TBL] [Abstract][Full Text] [Related]
26. Vascular endothelial growth factor in systemic lupus erythematosus: relationship to disease activity, systemic organ manifestation, and nailfold capillaroscopic abnormalities.
Kuryliszyn-Moskal A; Klimiuk PA; Sierakowski S; Ciołkiewicz M
Arch Immunol Ther Exp (Warsz); 2007; 55(3):179-85. PubMed ID: 17557150
[TBL] [Abstract][Full Text] [Related]
27. Emerging roles of endoglin/CD105 and angiogenic cytokines for disease development and progression in multiple myeloma patients.
Pappa CA; Alexandrakis MG; Boula A; Psarakis FE; Kolovou A; Bantouna V; Stavroulaki E; Tsirakis G
Hematol Oncol; 2013 Dec; 31(4):201-5. PubMed ID: 23576184
[TBL] [Abstract][Full Text] [Related]
28. Circulating endothelial cells in Behçet's disease: is there a relationship with vascular involvement?
Yaşar Bilge NŞ; Akay OM; Gunduz E; Bilgin M; Kasifoglu T
Clin Exp Rheumatol; 2019; 37 Suppl 121(6):105-110. PubMed ID: 31856936
[TBL] [Abstract][Full Text] [Related]
29. Clinical significance of nailfold capillaroscopy in systemic lupus erythematosus: correlation with endothelial cell activation markers and disease activity.
Kuryliszyn-Moskal A; Ciolkiewicz M; Klimiuk PA; Sierakowski S
Scand J Rheumatol; 2009; 38(1):38-45. PubMed ID: 18991188
[TBL] [Abstract][Full Text] [Related]
30. Role of T helper 17 cells in the pathogenesis of systemic lupus erythematosus.
Abou Ghanima AT; Elolemy GG; Ganeb SS; Abo Elazem AA; Abdelgawad ER
Egypt J Immunol; 2012; 19(2):25-33. PubMed ID: 23885404
[TBL] [Abstract][Full Text] [Related]
31. On the origin of (CD105+) circulating endothelial cells.
Strijbos MH; Verhoef C; Gratama JW; Sleijfer S
Thromb Haemost; 2009 Aug; 102(2):347-51. PubMed ID: 19652886
[TBL] [Abstract][Full Text] [Related]
32. Circulating TCR gammadelta cells in the patients with systemic lupus erythematosus.
Robak E; Błoński JZ; Bartkowiak J; Niewiadomska H; Sysa-Jedrzejowska A; Robak T
Mediators Inflamm; 1999; 8(6):305-12. PubMed ID: 10815619
[TBL] [Abstract][Full Text] [Related]
33. The use of angiogenic and antiangiogenic factors in the differential diagnosis of pre-eclampsia, antiphospholipid syndrome nephropathy and lupus nephritis.
de Jesus GR; de Jesus NR; Levy RA; Klumb EM
Lupus; 2014 Oct; 23(12):1299-301. PubMed ID: 25228732
[TBL] [Abstract][Full Text] [Related]
34. Plasma levels of angiogenic factors and circulating endothelial cells in essential thrombocythemia: correlation with cytoreductive therapy and JAK2-V617F mutational status.
Treliński J; Wierzbowska A; Krawczyńska A; Sakowicz A; Pietrucha T; Smolewski P; Robak T; Chojnowski K
Leuk Lymphoma; 2010 Sep; 51(9):1727-33. PubMed ID: 20615083
[TBL] [Abstract][Full Text] [Related]
35. Clinical significance of selected endothelial activation markers in patients with systemic lupus erythematosus.
Kuryliszyn-Moskal A; Klimiuk PA; Ciolkiewicz M; Sierakowski S
J Rheumatol; 2008 Jul; 35(7):1307-13. PubMed ID: 18484695
[TBL] [Abstract][Full Text] [Related]
36. Serum levels of vascular endothelial growth factor in children and adolescents with systemic lupus erythematosus.
Heshmat NM; El-Kerdany TH
Pediatr Allergy Immunol; 2007 Jun; 18(4):346-53. PubMed ID: 17346298
[TBL] [Abstract][Full Text] [Related]
37. Increased expression of soluble inducible costimulator ligand (ICOSL) in patients with systemic lupus erythematosus.
Her M; Kim D; Oh M; Jeong H; Choi I
Lupus; 2009 May; 18(6):501-7. PubMed ID: 19395451
[TBL] [Abstract][Full Text] [Related]
38. Anti-Endothelin Receptor Type A Autoantibodies in Systemic Lupus Erythematosus-Associated Pulmonary Arterial Hypertension.
Guo L; Li M; Chen Y; Wang Q; Tian Z; Pan S; Zeng X; Ye S
Arthritis Rheumatol; 2015 Sep; 67(9):2394-402. PubMed ID: 26018988
[TBL] [Abstract][Full Text] [Related]
39. Shedding of endothelial protein C receptor contributes to vasculopathy and renal injury in lupus: in vivo and in vitro evidence.
Sesin CA; Yin X; Esmon CT; Buyon JP; Clancy RM
Kidney Int; 2005 Jul; 68(1):110-20. PubMed ID: 15954900
[TBL] [Abstract][Full Text] [Related]
40. Th1/Th2/Th17/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: Correlation with disease activity.
Talaat RM; Mohamed SF; Bassyouni IH; Raouf AA
Cytokine; 2015 Apr; 72(2):146-53. PubMed ID: 25647269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
